Abstract: Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of an ointment, cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. The composition is variably effective to treat visceral, somatic and neuropathic pain both acute and chronic as well as muscle pain and stiffness and joint pain and stiffness.

Abstract: Calcium phosphate and related coating powder particles comprising a surface component comprising a silicate content, plasma sprayed coatings thereof on implantable medical/dental devices, and bone grafting materials of such coated particles. Optionally, biologically active agents such as bone morphogenetic proteins, growth factors, analgesics, and antibiotics can be incorporated therein.

Abstract: A controlled release particle includes a core formed by suspension polymerization of a core ingredient component containing an antibiotic compound and a first polymerizable vinyl monomer, and containing a first polymer of the first polymerizable vinyl monomer and the antibiotic compound present in the first polymer; and a shell formed by suspension polymerization of a second polymerizable vinyl monomer having affinity with water of the same or higher than that of the first polymerizable vinyl monomer, containing a second polymer obtained from the second polymerizable vinyl monomer, and covering the core.

Abstract: The present invention relates to a material as interpenetrating polymer network (IPN) associating a gel with a co-network of functionalized synthetic polymer and functionalized protein as well as a method of the manufacture of such a material. In particular, the invention relates to a material as interpenetrating polymer network associating a fibrin gel with a co-network of polyvinylalcohol and albumin thank to methacrylate bridges, with improved biodegradability properties.

Abstract: The present invention relates to a mixture comprising or consisting of a) 2,2-Dimethyl-3-(3-methylphenyl)-propanol (Majantol) b) 4,4a,5,9b-Tetrahydro-2,4-dimethylindenol[1,2-d]-m-dioxin (Magnolan) and optionally, one, two, three or all of the compounds selected from the group consisting of: c) 2-Isobutyl-4-methyltetrahydro-2H-pyran-4-ol (Florosa) d) Citronellyloxyacetaldehyde (Mugenal) e) 4-n-decylpyridine (Symmarine) f) 4-(4-methyl-3-penten-1-yl)-3-cyclohexene carboxaldehyde (Vertomugal), to a fragrance composition containing an organoleptically effective amount of said mixture and to a perfumed product containing said mixture or said fragrance composition and to a method of imparting an odor to a product or enhancing an odor of a product by adding to the product or incorporating into the product an organoleptically effective amount of a mixture or a fragrance composition according to the invention.

Abstract: The application discloses a discus-shaped unit of a tablet or granulates which contain abrasive media, to be dissolved into a stream of water. Tablet or granulates are encased in a flexible, but inherently stable mesh of filaments for to enhance dissolution, avoid clogging nozzles and ease disposal of residues.

Abstract: A calcium phosphate/copper coating for an implant is provided which includes highly porous calcium phosphate and predominantly discontinuously distributed copper. The highly porous calcium phosphate first forms a highly porous calcium phosphate layer in which the copper has been incorporated so as to be discontinuously distributed, to form the calcium phosphate/copper coating. Further provided are a method of producing such a calcium phosphate/copper coating and an implant coated therewith.

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Abstract: Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose.

Abstract: Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.

Abstract: The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Abstract: Embodiments of a multi-purpose implant for use in surgery, such as for reconstruction of soft tissues, are disclosed. In some embodiments, the implant includes elastic polymer film made from a suitable biologically compatible polymer. The implant also includes a reinforcement element formed from a polyurethane mesh or other strong and stable woven or unwoven synthetic material. The reinforcement element can be fully enclosed by the film so that only the film comes into contact with the organs and tissues. Anti-adhesive properties or control over implant's integration into a body can be determined by the preset surface structure of the implant, while physical and mechanical properties, such as strength and elasticity of the implant, are obtained by virtue of reinforcement element geometry.

Abstract: A biocide is formed by mixing at least one of ammonium sulfamate and ammonium carbamate with an aqueous solution of a hypochlorite oxidant at a molar ratio of ammonium to hypochlorite of at least 1:1. The biocide is useful in treating microbial or biofilm growth, pulp and paper process water, cooling tower water, waste water, reclaimed waste water, sludge, colloidal suspensions, irrigation water or a medium having a reducing capacity.

Abstract: The invention provides a method for producing a polymeric photoinitiator of the general formula I: Polymer-[CR2-CHR-Spacer (PI)n]m, (I) wherein m is an integer from 1-5000; n is a real number above 0 and below 5; each R group, independently, is a substituent independently selected from hydrogen, C1-C25 linear alkyl, C3-C25 branched alkyl, C3-C25 cycloalkyl, aryl, heteroaryl, —OH, —CN, halogens and amines and PI is a photoinitiator moiety. The method comprises grafting one or more photoinitiator moieties (PI), each of which comprises at least one activated alkene functional group, onto the polymer. Polymeric photoinitiators are also provided.

Abstract: Provided is a flowable bioresorbable tissue dressing comprising a gas-forming porogen and a gel or gel-forming solution. Also provided is kits for preparing the above-described tissue dressing. Further provided are methods of treating a tissue site of a mammal with the above dressing. Also provided is a reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site.

Abstract: A solid exfoliating composition includes a surfactant, sodium bicarbonate, cream of tartar, and a granular exfoliant.

Abstract: The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution.

Abstract: Disclosed is a multi-layered structure for drug reservoir, comprising a first micelle layer for crosslinking and adhesion, comprising a drug, a multi-arm polymer, a phenol derivative, and a dopa derivative and having a one or two-layered structure; a second micelle layer for crosslinking, being stacked on the first micelle layer, comprising a drug, a multi-arm polymer, and a phenol derivative, and having a one or two-layered structure; and a physiologically active material layer, being stacked on the second micelle layer, comprising a physiologically active material, a water-soluble polymer, and a phenol derivative, and having a one or two-layered structure.

Abstract: A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.

Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.